- Home
- PVLA vs AKBA Comparison
PVLA vs AKBA Comparison
Compare PVLA & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVLA
- AKBA
- Stock Information
- Founded
- PVLA 2015
- AKBA 2007
- Country
- PVLA United States
- AKBA United States
- Employees
- PVLA N/A
- AKBA N/A
- Industry
- PVLA Biotechnology: Pharmaceutical Preparations
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- PVLA Health Care
- AKBA Health Care
- Exchange
- PVLA Nasdaq
- AKBA Nasdaq
- Market Cap
- PVLA 888.0M
- AKBA 729.1M
- IPO Year
- PVLA N/A
- AKBA 2014
- Fundamental
- Price
- PVLA $81.40
- AKBA $1.76
- Analyst Decision
- PVLA Strong Buy
- AKBA Strong Buy
- Analyst Count
- PVLA 13
- AKBA 6
- Target Price
- PVLA $99.38
- AKBA $6.25
- AVG Volume (30 Days)
- PVLA 163.2K
- AKBA 6.5M
- Earning Date
- PVLA 11-11-2025
- AKBA 11-10-2025
- Dividend Yield
- PVLA N/A
- AKBA N/A
- EPS Growth
- PVLA N/A
- AKBA N/A
- EPS
- PVLA N/A
- AKBA N/A
- Revenue
- PVLA N/A
- AKBA $225,071,000.00
- Revenue This Year
- PVLA N/A
- AKBA $53.38
- Revenue Next Year
- PVLA N/A
- AKBA $30.53
- P/E Ratio
- PVLA N/A
- AKBA N/A
- Revenue Growth
- PVLA N/A
- AKBA 32.49
- 52 Week Low
- PVLA $11.17
- AKBA $1.52
- 52 Week High
- PVLA $85.30
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- PVLA 59.88
- AKBA 32.77
- Support Level
- PVLA $78.99
- AKBA $1.64
- Resistance Level
- PVLA $85.03
- AKBA $1.89
- Average True Range (ATR)
- PVLA 5.58
- AKBA 0.16
- MACD
- PVLA -0.02
- AKBA -0.04
- Stochastic Oscillator
- PVLA 63.39
- AKBA 18.69
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.